Surveillance costs and appropriateness of surgery of “low-risk” BD-IPMNs are relevant issues. In this study we evaluated the rate of correct indication for pancreatectomy defined as high grade dysplasia (HGD) at histology in 961 patients who underwent surveillance for a median of 5.1 years. Undertreatment and overtreatment were defined as invasive cancer and low grade dysplasia (LGD) at histology, respectively. Of the 66 patients (6.9%) who were operated, only 16 (23.8%) had a HGD while 40 (59.7%) had a LGD and 10 (14.9%) an invasive cancer, without differences regarding timing of surgery. The mean surveillance cost was € 194.9 ± 107.6 per patient-year, with a median cost of € 277.1 ± 148.2 in the correct surgery group compared with € 222.7 ± 111.6 and € 197 ± 102.7 in the overtreatment and undertreatment groups. The surveillance mean cost from diagnosis to surgery was € 854.8. Rate of appropriate surgery in BD-IPMNs under surveillance is low.

Tamburrino, D., Cortesi, P., Facchetti, R., de Pretis, N., Perez-Cuadrado-Robles, E., Uribarri-Gonzalez, L., et al. (2023). Real-world costs and dynamics of surveillance in patients who underwent surgery for low-risk branch duct intraductal papillary mucinous neoplasms. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 49(1 (January 2023)), 137-141 [10.1016/j.ejso.2022.08.033].

Real-world costs and dynamics of surveillance in patients who underwent surgery for low-risk branch duct intraductal papillary mucinous neoplasms

Cortesi P.
Secondo
;
Facchetti R.;Mantovani L. G.;
2023

Abstract

Surveillance costs and appropriateness of surgery of “low-risk” BD-IPMNs are relevant issues. In this study we evaluated the rate of correct indication for pancreatectomy defined as high grade dysplasia (HGD) at histology in 961 patients who underwent surveillance for a median of 5.1 years. Undertreatment and overtreatment were defined as invasive cancer and low grade dysplasia (LGD) at histology, respectively. Of the 66 patients (6.9%) who were operated, only 16 (23.8%) had a HGD while 40 (59.7%) had a LGD and 10 (14.9%) an invasive cancer, without differences regarding timing of surgery. The mean surveillance cost was € 194.9 ± 107.6 per patient-year, with a median cost of € 277.1 ± 148.2 in the correct surgery group compared with € 222.7 ± 111.6 and € 197 ± 102.7 in the overtreatment and undertreatment groups. The surveillance mean cost from diagnosis to surgery was € 854.8. Rate of appropriate surgery in BD-IPMNs under surveillance is low.
Articolo in rivista - Articolo scientifico
Branch-duct IPNM; Cost-effectiveness; EUS; Intraductal papillary mucinous neoplasm; Pancreas; Pancreatic cystic neoplasm; Pancreatic surgery;
English
31-ago-2022
2023
49
1 (January 2023)
137
141
reserved
Tamburrino, D., Cortesi, P., Facchetti, R., de Pretis, N., Perez-Cuadrado-Robles, E., Uribarri-Gonzalez, L., et al. (2023). Real-world costs and dynamics of surveillance in patients who underwent surgery for low-risk branch duct intraductal papillary mucinous neoplasms. EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 49(1 (January 2023)), 137-141 [10.1016/j.ejso.2022.08.033].
File in questo prodotto:
File Dimensione Formato  
Tamburrino-2023-EJSO-VoR.pdf

Solo gestori archivio

Descrizione: Short communication
Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Tutti i diritti riservati
Dimensione 288.62 kB
Formato Adobe PDF
288.62 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/402343
Citazioni
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
Social impact